Profile data is unavailable for this security.
About the company
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
- Revenue in INR (TTM)164.68bn
- Net income in INR10.65bn
- Incorporated1977
- Employees13.48k
- LocationGlenmark Pharmaceuticals LtdB D S MargChakala, Off Western Express HighwayAndheri (E),MUMBAI 400099IndiaIND
- Phone+91 2 240189999
- Fax+91 2 240189986
- Websitehttps://glenmarkpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 282.22bn | 6.73k | 32.43 | -- | 21.70 | 3.19 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Gland Pharma Ltd | 61.13bn | 8.47bn | 293.40bn | 4.35k | 34.63 | -- | 23.32 | 4.80 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 41.93bn | 7.54bn | 303.69bn | 5.52k | 39.88 | -- | 32.56 | 7.24 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
| Ajanta Pharma Ltd | 52.02bn | 10.15bn | 364.82bn | 9.63k | 35.96 | -- | 30.86 | 7.01 | 81.21 | 81.21 | 416.34 | -- | -- | -- | -- | 5,402,607.00 | -- | 17.31 | -- | 21.48 | 77.65 | 73.83 | 19.50 | 19.60 | -- | 96.70 | -- | 33.78 | 10.44 | 12.43 | 12.77 | 14.50 | 5.84 | 26.43 |
| IPCA Laboratories Ltd | 71.12bn | 5.84bn | 376.85bn | 18.04k | 64.57 | -- | 27.73 | 5.30 | 23.00 | 35.86 | -- | -- | -- | -- | -- | 3,941,717.00 | -- | 9.16 | -- | 12.39 | 70.13 | 60.24 | 13.33 | 11.25 | -- | 14.07 | -- | 13.42 | 16.02 | 13.97 | 34.77 | 4.00 | 20.42 | 9.86 |
| Anthem BioSciences Ltd | 19.97bn | 4.85bn | 387.55bn | 2.06k | 80.31 | -- | 63.58 | 19.41 | 8.59 | 8.59 | 35.41 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| GlaxoSmithKline Pharmaceuticals Ltd | 38.01bn | 10.21bn | 439.51bn | 3.11k | 43.05 | -- | 40.36 | 11.56 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Laurus Labs Ltd | 67.22bn | 8.43bn | 545.58bn | 6.17k | 64.74 | -- | 41.64 | 8.12 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 562.26bn | 3.66k | 36.89 | -- | 35.16 | 8.24 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 563.72bn | 13.48k | 52.95 | -- | 34.89 | 3.42 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Alkem Laboratories Ltd | 138.90bn | 23.61bn | 645.95bn | 18.64k | 27.36 | 4.84 | 23.16 | 4.65 | 197.47 | 197.47 | 1,161.71 | 1,116.21 | 0.7427 | 1.71 | 4.97 | 7,451,003.00 | 12.89 | 12.12 | 17.55 | 17.53 | 63.60 | 60.06 | 17.35 | 14.69 | 1.87 | 18.59 | 0.1457 | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Aurobindo Pharma Ltd | 331.82bn | 34.87bn | 665.37bn | 9.11k | 19.08 | -- | 12.72 | 2.01 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
Data as of Feb 16 2026. Currency figures normalised to Glenmark Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
19.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 17.15m | 6.08% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 9.85m | 3.49% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 5.50m | 1.95% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Jan 2026 | 5.22m | 1.85% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 3.76m | 1.33% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 3.45m | 1.22% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 3.28m | 1.16% |
| Mahindra Manulife Investment Management Pvt Ltd.as of 31 Jan 2026 | 2.78m | 0.99% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.39m | 0.85% |
| Edelweiss Asset Management Ltd.as of 31 Jan 2026 | 2.32m | 0.82% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
